← 返回

结直肠癌免疫治疗的过去、现在和未来

英文原题:The past, present, and future of immunotherapy for colorectal cancer.

查看英文原题

The past, present, and future of immunotherapy for colorectal cancer.

PubMed 2023/02/14(内容时间) Med Oncol Q2 · IF 4.7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

结直肠癌在全球范围内普遍存在,多种因素影响晚期转移性病例的生存率。当前的标准治疗包括手术切除、辅助化疗和新辅助化疗。新型免疫治疗研究在包括结直肠癌在内的多种癌症类型中显示出有希望的结果。当前的免疫治疗选择仅限于结直肠癌的特定分子亚型,而其余则限于标准方案。这篇综述文章总结了通过主动特异性、检查点抑制剂、细胞因子、细胞毒性和过继性 T 细胞免疫治疗用于新型结直肠癌免疫治疗的已批准、正在开发和潜在来源。这样的研究将对结直肠癌患者有益。

展开英文摘要原文

Colorectal cancer is prevalent worldwide, with various factors influencing the survival rate of late-stage metastatic cases. Current standard treatments include surgical removal, adjuvant chemotherapy, and neoadjuvant chemotherapy. Novel immunotherapy research shows promising results for various cancer types, including colorectal cancer.

Current immunotherapy options are limited to specific molecular subtypes of colorectal cancer, while the remaining are limited to standard protocol. This review article summarizes approved, developing, and potential sources for novel colorectal cancer immunotherapy treatment through active-specific, checkpoint inhibitor, cytokine, cytotoxic, and adoptive T-cell immunotherapy. Such a study would be beneficial to patients with colorectal cancer.

论文信息

作者
Formslag CR、Zhao L、Heslin AJ、Lewis CC、Miller CW、Bai Q、Wakefield MR、Fang Y
第一作者单位
Department of Microbiology, Immunology & Pathology, Des Moines University, Des Moines, IA, 50312, USA.United States
通讯作者单位
Department of Microbiology, Immunology & Pathology, Des Moines University, Des Moines, IA, 50312, USA. yujiang.fang@dmu.edu.United States
文献类型
综述
期刊
Medical oncology (Northwood, London, England)2023 Feb 14
原文标识
PubMed 36786890 · DOI 10.1007/s12032-023-01967-1